Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological interventions for stroke: failures and future.

Jeffrey J Legos1, Ronald F Tuma, Frank C Barone

  • 1High Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA. Jeffrey_J_Legos@gsk.com

Expert Opinion on Investigational Drugs
|May 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA-Based Biomarkers for Diagnostic Discrimination of Ischemic and Hemorrhagic Stroke: A Systematic Review.

Journal of clinical medicine·2026
Same author

Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progress.

GeroScience·2025
Same author

The future of biomarkers for vascular contributions to cognitive impairment and dementia (VCID): proceedings of the 2025 annual workshop of the Albert research institute for white matter and cognition.

GeroScience·2025
Same author

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review.

Frontiers in neurology·2024
Same author

Remote Monitoring and Data Collection for Decentralized Clinical Trials.

JAMA network open·2024
Same author

Neuroprotective effect of the RNS60 in a mouse model of transient focal cerebral ischemia.

PloS one·2024
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Novel therapeutic strategies for ischemic stroke are critical due to trial failures. This review examines vascular targets and neuroprotective agents, considering stroke

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Pharmacology

Background:

  • Limited therapeutic options exist for ischemic stroke patients.
  • Recent Phase III clinical trial failures highlight the urgent need for new treatments.
  • Brain injury in stroke evolves slowly over hours, potentially due to progressive microcirculatory failure.

Purpose of the Study:

  • To review recent clinical failures in stroke therapy.
  • To examine agents currently in clinical development for stroke.
  • To compare vascular targets with traditional neuroprotective strategies.

Main Methods:

  • Literature review of clinical trial outcomes.
  • Analysis of pathophysiological mechanisms in stroke.
  • Comparison of therapeutic approaches targeting vascular and neuronal pathways.

Related Experiment Videos

Main Results:

  • Several large-scale clinical trials for stroke therapies have failed.
  • Pathophysiological changes include free radical production, excitotoxicity, ionic imbalance, inflammation, and endothelial dysfunction.
  • These changes can lead to increased vascular resistance and hypoperfusion, exacerbating brain injury.

Conclusions:

  • The failures underscore the complexity of stroke pathophysiology.
  • Further research into novel therapeutic targets, particularly vascular-focused ones, is essential.
  • A comparative analysis of vascular versus neuroprotective strategies is needed to guide future drug development.